An observational real-world study of two geographically separated Italian cohorts found that GLP-1 RA use decreased rates of PAD (Lombardy cohort: HR 0.72, 95% CI [0.64–0.82]; Apulia cohort: HR 0.80, 95% CI 0.67–0.98) and lower limb complications (Lombardy cohort: HR 0.67, 95% CI [0.56–0.81]; Apulia cohort: HR 0.69, 95% CI [0.51–0.93]) [75]. This evidence concerns the gene GCG and peripheral arterial disease.